Cardiovascular risk assessment in patients with type 2 diabetes mellitus and metabolic syndrome: Role of biomarkers

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 5, Issue 1, 2011, Pages 7-11

  Kanbak, Gungor ^a   Akalin, Aysen ^a   Dokumacioglu, Ali ^a   Ozcelik, Eda ^a   Bal, Cengiz ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Cardiovascular disease; Metabolic syndrome; Nitric oxide; Paraoxonase; Total sialic acid; Type 2 diabetes mellitus

Indexed keywords

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; SIALIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; WAIST CIRCUMFERENCE;

ADULT; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; NITRIC OXIDE; RISK ASSESSMENT;

EID: 79955977695     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2010.05.006     Document Type: Article

References (39)

1. Lakka HM, Laaksonen DE, Lakka TT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16. (Pubitemid 35403784)
2. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001;44:1148-54. (Pubitemid 32842461)
3. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004;27:2689-94. (Pubitemid 39441471)
4. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81. (Pubitemid 34517204)
5. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metabol 2001;86:713-8. (Pubitemid 32207485)
6. Sobel BE. Insulin resistance and thrombosis: a cardiologist's view. AmJ Cardiol 1999;84:37-41.
7. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998;47:290-3. (Pubitemid 28079991)
8. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002;3:49-55. (Pubitemid 38234486)
9. Gopaul KP, Crook MA. Sialic acid: a novel marker of cardiovascular disease? Clin Biochem 2006;39:667-81.
10. Nakagami H, Ikeda U, Maeda Y, Yamamoto K, Hojo Y, Kario K, et al. Coronary artery disease and endothelial nitric oxide synthase and angiotensin-converting enzyme gene polymorphisms. J Thromb Thrombolysis 1999;8:191-5. (Pubitemid 29497772)
11. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507. (Pubitemid 26159866)
12. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272(August):20963-6. (Pubitemid 27373946)
13. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-91.
14. van Wijk J, Coll B, Cabezas MC, Koning E, Camps J, Mackness B, et al. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin Exp Pharmacol Physiol 2006;33:1134-7. (Pubitemid 44923898)
15. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) 2004;107:435-47. (Pubitemid 39506735)
16. Lindberg G, Eklund GA, Gullberg B, Rastam L. Serum sialic acid concentration and cardiovascular mortality. BMJ 1991;302:143-6.
17. Abdella N, Akanji AO, Moijiminiyi OA, Al Assoussi A, Moussa M. Relation of serum total sialic acid concentrations with diabetic complications and cardiovascular risk factors in Kuwaiti Type 2 diabetic patients. Diabetes Res Clin Pract 2000;50:65-72. (Pubitemid 30629021)
18. Yilmaz G, Yilmaz FM, Aral Y, Yucel D. Levels of serum sialic acid and thiobarbituric acid reactive substances in subjects with impaired glucose tolerance and type 2 diabetes mellitus. J Clin Lab Anal 2007;21:260-4. (Pubitemid 47556802)
19. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353:1649-52. (Pubitemid 29224520)
20. Lefer AM, Murohara T. Comparative pharmacology of nitric oxide and nitric oxide generators on cardiac contractility in mammalian species. Int J Cardiol 1995;50:239-42.
21. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001;285:2486-97.
22. Juretic D, Tadijanovic M, Rekic B, Simeon-Rudolf V, Reiner E, Baricic M. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J 2001;42:146-50. (Pubitemid 32525313)
23. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391-5.
24. Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 1990;36:1440-3.
25. Katopodis N, Hirshaut Y, Geller NL, Stock CC. Lipid-associated sialic acid test for the detection of human cancer. Cancer Res 1982;42:5270-5. (Pubitemid 13223181)
26. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. DiabetesMetab Res Rev 2006;22:423-36. (Pubitemid 44774046)
27. Hsueh WA, Quiñones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003;92:10-7.
28. Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation 2007;116:2119-26. (Pubitemid 350060349)
29. Forst T, Hohberg C, Pfützner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. Horm Metab Res 2009;41:123-31.
30. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007;61:548-53. (Pubitemid 46605227)
31. Onat A, Hergenç G, Can G. Prospective validation in identical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition. Anadolu Kardiyol Derg 2007;7:29-34. (Pubitemid 46540221)
32. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 2006;187:74-81.
33. Tomás M, Sentí M, García-Faria F, Vila J, Torrents A, Covas M, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000;20:2113-9.
34. van den Berg SW, Jansen EH, Kruijshoop M, Beekhof PK, Blaak E, van der Kallen CJ, et al. Paraoxonase 1 phenotype distribution and activity differs in subjects with newly diagnosed Type 2 diabetes (the CODAM Study). Diabet Med 2008;25:186-93.
35. Zahedi Asl S, Ghasemi A, Azizi F. Serum nitric oxide metabolites in subjects with metabolic syndrome. Clin Biochem 2008;41:1342-7.
36. Ozden S, Tatlipinar S, Biçer N, Yaylali V, Yildirim C, Ozbay D, et al. Basal serum nitric oxide levels in patients with type 2 diabetes mellitus and different stages of retinopathy. Can J Ophthalmol 2003;38:393-6. (Pubitemid 37295125)
37. Yoon Y, Song J, Hong SH, Kim JQ. Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clin Chem 2000;46(10):1626-30.
38. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241-8.
39. Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med 2007;48:1800-15. (Pubitemid 350099325)